Reconciling vector yield, recovery and potency across AAV campaigns

Across sites, programs and functions

An authorized AAV program project brings together approved source exports across production and purification campaigns. Serotype/capsid, vector construct, cell system, process version and assay basis define the comparison. The method may be reused across a vector portfolio, but unlike constructs and analytical populations are not pooled. The use case is AAV-specific; it does not imply that the same assays or process model apply to every viral-vector platform.

Continuity as new campaigns arrive

Incoming campaigns preserve the relation between run, harvest stream, purification fraction, pool and analytical sample. Changed assay targets, standards or methods require review before historical values are combined. Evidence from partners follows agreed project permissions and source delivery; no automatic cross-company access is assumed.

Reconstruct the incident before ranking performance

Initial signal

A program review sees favorable vector-genome concentration in selected campaigns but inconsistent total recovery and final quality evidence. The investigation asks whether the difference begins in production, harvest partitioning or purification pooling.

Enterprise complexity

Sites may report genome titer, capsid titer and functional response on different assay bases. Concentration changes during processing, and a fraction can be analytically rich yet contribute little total recovered material. Pool boundaries also determine what reaches the final sample.

Decisive comparison

Restrict to the relevant construct/capsid and reviewed assay basis. Connect volume to each titer sample, follow streams and fractions, then compare final genome, capsid and functional evidence as separate responses.

The comparison is scoped by business and scientific context. Data volume is not used as a proxy for comparability, relevance or evidence quality.

Separate genome quantity, capsid attributes and function

Titer and total quantity answer different questions

A volume change can increase concentration without increasing recovered vector. Total genome quantity requires the relevant genome-titer and stream volume on a compatible basis. Avoid counting the same stream twice or treating an analytical aliquot as the full pool.

Genome, capsid and function are distinct

Genome titer, capsid quantity, occupancy measures and functional assays reflect different properties. A higher full-capsid fraction is not automatically greater potency, and a genome/capsid ratio is not a universal full/empty measurement without a supported method interpretation.

Assay basis and integrity matter

Genome target, reference standard, sample treatment and method can affect comparison. A detected target region alone does not establish intact packaged genome. Retain the relevant integrity and impurity evidence rather than inferring it from one assay result.

Pool decisions require multiple responses

Evaluate recovery alongside the product-specific quality and functional evidence. A narrow pool may improve one attribute while reducing total recovery. Confirm that trade-off experimentally on comparable material; do not imply clinical efficacy from an analytical ranking.

A focused conclusion and a confirmation plan

Interpret the evidence through explicit decision paths, then confirm the hypothesis with the agreed study.

The decision output distinguishes upstream production, harvest/stream accounting and purification pooling. Reviewers see total quantity and separate quality/function responses on an agreed assay basis. The next study tests a defined process or pool decision rather than declaring a higher-titer campaign universally better.

Make the method repeatable across the enterprise

Vector-program ownership

Own construct/capsid identity, cell system and process-version scope.

Process and purification ownership

Own harvest partitioning, fraction membership, volumes and pooling assumptions.

Analytical review

Own genome/capsid/function assay suitability, standards and interpretation of occupancy and integrity evidence.

Quality and deployment ownership

Define evidence review and partner delivery; verify access, supported modality behavior and model eligibility for the deployment.

Operating-model requirements are deployment-specific. Validate role/access behavior, reviewer workflows, retention, model governance and source delivery for the intended environment; this scenario does not assert certification or production readiness.

Measure recovered vector evidence and decision readiness

The enterprise value is a shared view of what the AAV process actually recovered and how that material was characterized, without collapsing unlike measurements into one performance score.

A credible benefit assessment

Choose a baseline period and comparable investigation or campaign scope. Record how elapsed time, review effort or process response is measured. Separate improvement in data preparation from improvement in scientific interpretation, and separate both from any measured manufacturing result. Include adverse, inconclusive and unchanged outcomes.

What leadership receives

A defined investigation scope; a common evidence basis for the participating teams; a documented conclusion with remaining uncertainty; and a confirmation plan with owners. Portfolio expansion follows demonstrated reuse and the required deployment checks, rather than an assumption that one successful analysis establishes every use case.